Clinical trials: Acquired Immune Deficiency Syndrome
HIV Infections, Acquired Immunodeficiency Syndrome
Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya
Both antiretroviral therapy (ART) and prevention of opportunistic infections (OIs) have been associated with significantly decreased mortality in HIV-infected individuals.
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Disease Progression, Immune System Diseases
- Trial name
- NCT01425073
- Testing
- Discontinue TMP/SMZ prophylaxis
- Where
- 2 sites in Kenya
- Volunteers
- 500 people
- Sponsor
- University of Washington
Cytomegalovirus Retinitis, HIV Infections
A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy
AMENDED: 04-12-91 Population of patients changed FROM those who are intolerant of systemic therapy with NON-sight-threatening CMV retinitis TO those AIDS patients intolerant of systemic therapy with CMV retinitis.
- Trial name
- NCT00000673
- Testing
- Ganciclovir
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sarcoma, Kaposi, HIV Infections
A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections.
- Trial name
- NCT00002262
- Testing
- Tumor Necrosis Factor
- Where
- United States
- Sponsor
- University of California, San Francisco
HIV/AIDS
Can Undetectable (Viral Load) = Untransmissible (Virus) Change the Life Course of Adolescents Living in Africa
The scientific breakthrough related to Undetectable (viral load) = Untransmissible (virus) has had a major impact on motivation to take up and adhere to antiretroviral therapy among people living with HIV all over the world.
- Trial name
- NCT05278559
- Where
- Zimbabwe
- Volunteers
- 300 people
- Sponsor
- Centre for Sexual Health and HIV/AIDS Research Zimbabwe
Hepatitis, HIV/AIDS
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Background: Standard treatment for the hepatitis C virus (HCV) is a combination of the drugs peg-IFN and ribavirin. However, this treatment is not very effective in people with a serious type of HCV (HCV genotype 1) and also in…
- Trial name
- NCT01443923
- Testing
- Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Disease
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
In this study we will use a multi-modal imaging approach of MRS and fMRI to comprehensively assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF), specifically alterations in the brain…
- Trial name
- NCT01929759
- Testing
- Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
HIV (Human Immunodeficiency Virus), AIDS (Acquired Immune Deficiency Syndrome)
Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study
The aim of this study is to develop and follow a cohort of human immunodeficiency virus (HIV)-infected adults who are starting HIV drugs at health facilities in Kenya.
- Conditions
- HIV (Human Immunodeficiency Virus), AIDS (Acquired Immune Deficiency Syndrome), Tuberculosis, Non-communicable Diseases (NCD)
- Trial name
- iMACS (NCT02027480)
- Where
- 9 sites in Kenya
- Volunteers
- 685 people
- Sponsor
- Columbia University
COPD, HIV/AIDS
High-quality COPD Care for People With Immune Dysfunction Through Proactive E-consults
This study examines an intervention to promote effective, evidence-based care and de-implement inappropriate therapies for COPD in HIV-infected (HIV+) patients.
- Trial name
- ACHIEVE (NCT03856879)
- Testing
- Proactive E-consult
- Where
- 7 sites in United States
- Volunteers
- 270 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
HIV/AIDS
Comparison of the Body Roundness Index and A Body Shape Index With Body Fat and Visceral Fat in People Living With HIV.
The study compares the Body Roundness Index (BRI) and the A Body Shape Index (ABSI) with with body fat and visceral fat in people living with HIV.
- Trial name
- NCT07203261
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Queens College, The City University of New York
Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
The primary purpose of this study is to assess the rate of early discontinuation from randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason other than confirmation of the negative HIV…
- Trial name
- PEPDar (NCT01516970)
- Testing
- Darunavir/Ritonavir (DRV/r), Lopinavir in fixed combination with Ritonavir, Zidovudine
- Where
- 17 sites in Germany
- Volunteers
- 312 people
- Sponsor
- Janssen-Cilag G.m.b.H
Lymphoma, Non-Hodgkin, HIV Infections
The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer
To determine the safety and toxicity of high-dose systemic methotrexate (MTX) and dexamethasone (DEX) combined with zidovudine (AZT) and brain irradiation in patients with AIDS-related primary central nervous system (CNS)…
- Trial name
- NCT00000723
- Testing
- Methotrexate, Leucovorin calcium, Zidovudine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs
The purpose of this study is to gain information on how the type and amount of HIV present in certain places in the body and in the blood are affected when potent (powerful) anti-HIV drugs are given.
- Trial name
- NCT00007488
- Where
- 23 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus
A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
This study is a Phase I, open-label, single dose, mass balance study in a cohort of 6 healthy adult male subjects. The study will consist of: Screening evaluations, a treatment phase, and follow-up evaluations.
- Trial name
- NCT01273103
- Testing
- 200mg [14C]- GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis C, Human Immunodeficiency Virus
Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
This study observes the effects of newly developed direct-acting antiviral (DAA) treatments on the central nervous system (CNS) of individuals with chronic Hepatitis C (HCV).
- Trial name
- NCT02650024
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Hepatitis C, Human Immunodeficiency Virus
Maraviroc Efficacy for Hepatitis C
This is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and human immunodeficiency virus (HIV) and taking…
- Trial name
- MAVERIC (NCT02881762)
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Human Immunodeficiency Virus
Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)
The purpose of this study is to learn whether HIV-infected patients have blood abnormalities which could lead to heart attack or stroke, and to find out what factors may contribute to these abnormalities.
- Trial name
- NCT00244803
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Johns Hopkins University
Frailty Syndrome, HIV Infections
Effectiveness of a Multifactorial Intervention in Frailty Individuals With HIV Infection: HIDRA360
The goal of this quasi-experimental before/after study without equivalent control group is to to describe the prevalence of frail, pre-fragile and robust individuals in the study group before and after a multifactorial…
- Trial name
- HIDRA360 (NCT05832164)
- Testing
- Multifactorial intervention
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Hospital Costa del Sol
HIV Infections
Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors
This study will evaluate patients who have achieved virologic suppression (< 400 copies/mL) on any dual protease inhibitor (PI) combination, to determine whether patients can substitute both PIs with the single boosted PI…
- Trial name
- DVD (NCT00543101)
- Testing
- Darunavir (DRV/r), continue on current dual boosted PI
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Community Research Initiative of New England
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
Background: Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection.
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
- Trial name
- NCT00798265
- Testing
- Gardasil, Survey
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.